Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company has
signed non-exclusive licensing agreements with seven India-based generic
pharmaceutical manufacturers to expand access to its chronic hepatitis C
medicines in developing countries.
for Gilead Announces Generic Licensing Agreements to Increase Access to Hepatitis C Treatments in Developing Countries investment picks